Topic Archives: Novartis (NVS)

I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]

Please indulge Doc Gumshoe while he presents his musings on what’s going on in general in the health-care arena, and in particular, which new drugs are getting the FDA blessing and why, as well as which ones are getting the short straw.   My impressions and conclusions are in some cases only loosely based on […]

This article was originally published on March 21, 2019 when the “deadline” touted was March 25. We’ve lightly updated our piece below, but much of it (like the ad) is unchanged from March. The latest ad for Green Chip Stocks is a doozy — reminiscent of the many “the world is about to change” ads […]

Today we’ve got a teaser pitch from Marc Lichtenfeld to consider. It’s an ad for his Oxford Income Letter, but the “fountain of youth” pitch makes it sound like a wild ride of a biotech idea… so let’s dig in and see what we can find, shall we? Sometimes it’s best to start with the […]

Every now and then a reader sends in a question about one of the stock ideas teased by dividend.com, which is a service that looks for, you guessed it, dividend paying stocks. Their standard “tease” is that they send around some hints about the latest stock they’ve added to one of their “best” lists, but […]

We’ve seen a long stream of earnings reports and other worthwhile bits of data on Real Money Portfolio stocks since I last wrote to you, including some that actually included some interesting news, so prepare for a lot of quick updates…. Medical Properties Trust (MPW) reported another quarter of ho-hum… pretty much met the forecasts, […]

The article below was originally published on November 27, 2017, when Jeff Brown’s ads promoting the “God Key” started to show up in our inboxes. It has not been updated or revised, but the new versions of the ad from Brown are very similar to the ones we covered in November, including the description of […]

Remember Ernie Tremblay’s pitch about a “tiny South Texas lab” that was about to cure every disease using its revolutionary CD19 Cancer Vaccine technology, and ignite a bidding war following its fantastical release of exciting information on June 23? Well, it’s back. Not the stock, that’s still languishing around where it was before Tremblay got […]

[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends.  He does not typically write about specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]

[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Ho ho ho! And Happy Christmas to all […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “Thanks to you I’m much obliged Such a […]

[Ed. Note: Dr. KSS writes about biotech and medicine for the Irregulars. He has agreed to our trading restrictions, chooses his own topics and his thoughts and opinions are his own. His previous columns and recent comments can be found on his Stock Gumshoe page.] “He had never seen her body so abandoned, so unconscious […]

[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]

[Ed. Note: Dr. KSS writes for our Irregulars about medicine and biotech stocks. As always, he has agreed our trading restrictions, and his words and opinions are his own. You can find all of his previous articles here. And now, for some dim sum….] Greetings Irregulars, and welcome to Stock Gumshoe’s festive second BioDimSum shindig, a periodic round-up […]

[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though, he mentions a couple publicly traded companies). His words and opinions are his own.] The […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]

[ed note: Dr. KSS is a paid contributor to Stock Gumshoe who writes about biotech stocks for (and discusses them with) the Irregulars. He chooses his own topics, and his words and opinions are his alone. Enjoy!] Greetings fellow Irregulars!  You’ve all been waiting for it….our first-ever annual ceremony in which we look back on […]

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

Comments

  • Avatar

    MA and V growth is limited due to reasons: *Both have not been expressly permitted to step in to China that is the growt...

  • Avatar

    CRXPF is an OTC Pink slip. I avoid OTC pinks 99% of the time. Buy something like CECBF (CellCube Energy Storage System...

  • Avatar
  • Avatar

    Fwiw, this stock does screen cheap on ev/ebitda, and if they focus on free cash flow and share repurchase (as opposed to...

  • Avatar

    Thanks everyone for sharing your experience with this software. I ma interested to try out the system. I would appreciat...

  • Avatar

    Late to this one, behind in my email. Thought I would add in four other stocks that are supposedly Tom Gardner's top ho...

  • Avatar

    From the Office of the Trading System Investigator (TSI), Dated December 26, 2018: Basically it is as Jeff says, buy P...

  • Avatar

    The 5 stocks are off their highs as follows: -33% 07/24/18 high -32% 09/25/18 high -30% 10/09/18 high -6% 11/07/18 high...

  • Travis Johnson, Stock Gumshoe

    No, it's just that being illegal at the federal level makes it not worth the risk for large banks that operate in every ...

  • Avatar

    Live in AB Cda and I use Coinbase. One sided though, put in but can’t take out. Also,Capital One stopped allowing thei...

  • Avatar

    $NoTicker I did send a prepaid Mastercard with funds on it. No need to deposit it into a bank, IRS won't know. Di...

  • Avatar

    I downloaded the WeChat app to see what the fuss was about and doesn't appear to be designed for the US or EU market. Yo...

  • Avatar

    I signed up for a $49 no risk, full refund offer on Aug 24. This is what was charged to my MasterCard. "1 year Platin...

  • DrKSSMDPhD

    Rick raises here an incredibly important point which I think bears emphasis. Which is that in true addiction, the patien...

  • DrKSSMDPhD

    Hi lev: This is another situation where two companies are in a race and vying for the same space: here it's Cambridge-ba...

  • Avatar

    You couldn't give me an American Express card for $0 per year. I had one, made a $1500 purchase and the seller emailed ...

  • Avatar

    This is a interesting link on artificial intelligence used by MasterCard Be sure to check the hyper links in this link w...

  • Avatar

    HN, keep up the good work. I do so appreciate all of your great comments and information. I have several gold stocks too...

  • DrKSSMDPhD

    Well, I'm not sure exactly what he said. Bakris was a well-known advisor to Relypsa and so he is contractually forbidden...

  • Avatar

    MasterCard challenges Canadian developer community to build the next payments revolution at Masters of Code...

  • Avatar

    I had to look it up! EMV are the initials of the initial developers of the specification: Eurocard, MasterCard and Visa....

  • Travis Johnson, Stock Gumshoe

    Huge cost of new equipment, mostly, and a reluctance of banks to pay for it... particularly as long as Mastercard and Vi...

  • Avatar

    For those of you who own a business and will be using the new gold-chip microprocessor-readers, you might be interested ...

  • Avatar

    Doc, these health advisories to fellow Gummies are totally off the subject. Totally! However, they are some of the bes...

  • Avatar

    to Don Ross, you are fortunate they 'sold out' as they alternate touting the Penny Speculator and Penny Stock Breakouts....

  • DrKSSMDPhD

    JZ: Sangamo's is one approach to genetic disease. And a decade ago, one might have argued that its notions versus siRNA ...

  • Avatar

    MasterCard is buying minority interest in Monitise (approximately 10%) and announces agreement to use Monitise services....

  • Avatar

    Well if we're limiting it to income generating revenue only then I'll go with MasterCard (MA)....

  • Avatar

    As consumer: I already have visa, mastercard and Amex without paying any card fee. Why should I care about NFC on my pho...

  • Avatar

    Perhaps somebody should work on a fundamental indicator named "EPSPT", Electronic Payment Systems Product Tracker, OR "V...

  • Avatar

    There's huge money in services, which they're transitioning more and more into, but also huge amounts of competition. Ho...

  • Avatar

    I believe it was mastercard not visa...

  • Avatar

    Its not a question of will the turnover from credit card to NFC's happen, It a matter of when. It also looks like the sa...

  • Avatar

    For those that wanted the straightforward list, see below: #1 BIP – Brookfield Infrastructure Partners L.P. #2 GOOG ...

  • Avatar

    For those that wanted the straightforward list, see below: #1 BIP - Brookfield Infrastructure Partners L.P. #2 GOOG - ...

  • Avatar

    I've been trying to come up with an answer to that very same question myself for a while. And I'm afraid there is no sin...

  • Travis Johnson, Stock Gumshoe

    Hi Bernardo, There are a lot of companies working on this, the one large firm that's usually mentioned is the European ...

  • Avatar

    Well the great great Gumshoe has spoken ... and as a subscriber, he has nailed the Chinese Pharma Plays .. like sitting ...

  • Avatar

    If you mean for the Irregulars membership payments, you are more than welcome to pay with Visa or Mastercard, but Paypal...

  • Avatar

    Please use Visa nd Mastercard along with your Paypal....

  • Avatar

    Mastercard and Visa have a class action lawsuit against them by various associations of restaurants, retailers, gas stat...

  • Avatar

    Thanks for the comments, folks -- yes, I imagine it's too late for much of anyone to get the initial allocation here, it...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info